Ethyl 4-(4′-heptanoyloxyphenyl)-6-methyl-3,4-dihydropyrimidin-2-one-5-carboxylate Prevents Progression of Monocrotaline-induced Pulmonary Arterial Hypertension in Rats

Therapies to prevent onset and progression of pulmonary arterial pressure are not very effective yet. This study was designed to investigate the effects of a novel dihydropyrimidinone, ethyl 4-(4′-heptanoyloxyphenyl)-6-methyl-3,4-dihydropyrimidin-2-one-5-carboxylate (H-DHPM) on pathogenesis of monocrotaline (MCT)-induced pulmonary arterial hypertension (PAH). For the same purpose, rats were injected intraperitoneally (i.p.) a single dose (60 mg/kg) of MCT which led to development of PAH in 21 days. MCT insult caused high mortality, pulmonary vascular and parenchymal remodelling. Since the course of PAH pathogenesis is characterised by an early onset and progression phases, H-DHPM was administered i.p. at 30 mg/kg dosage in MCT pre-injected animals either from day 0 through day 21 or day 14 though day 21 of MCT injection in two separate treatment groups. H-DHPM significantly improved survival, prevented remodelling of pulmonary vasculature and parenchyma and subsequently ameliorated PAH pathogenesis. Moreover, we observed significant decrease in right ventricle hypertrophy, measured by wet weight of right ventricle (RV) divided by wet weight of left ventricle plus septum (LV+S), in H-DHPM treated groups as compared to MCT injected animals. These findings suggest H-DHPM not only prevented development of PAH but also treated the PAH pathogenesis in progressive phase. In conclusion, our data determines H-DHPM, might be a future drug for the prevention of PAH

Protein Profile of Human Lung Epithelial Cells (A549) Revealing Deviation in Cytoskeleton Proteins in Response to Zinc Oxide Nanoparticles Exposure

Zinc oxide nanoparticles (ZnO NPs) are widely used in biomedicine and scientific research because of their high dissolution property and bioavailability. On the contrary, this property also increases the intracellular reactivity, accessibility and cytotoxicity. These nano-bio interactions could induce undesirable changes in the proteome of the interacting cells, especially in the lung cells as these are the primary contact site. However, the potential effects of ZnO NPs exposure on proteome remain unclear. Proteomics data will substantiate the detailed mechanism of cellular interactions and modulatory effects of ZnO NPs on cells. Quantitative proteomic profiling was done using MALDI-TOF/TOF and MS/MS to identify differential protein expression on exposure to NPs among non exposed and exposed cells. Twenty-two proteins, with approximately 1.5 fold differential expression in cells exposed to ZnO NPs as compared to control cells were identified. Differentially expressed proteins were further classified using PANTHER software on the basis of functional gene ontology term: molecular function, biological process and cellular component. ToppGene suite was used to study protein-protein interaction and network was enriched with STRING. This study is a systematic analysis of protein modulation of the A549 cells exposed to ZnO NPs indicating alterations in the cytoskeleton

Kynurenines Dynamics in the Periphery and Central Nervous System Steers Behavioral Deficits in Rats under Hypobaric Hypoxia

People travel to high-altitude regions as tourists, workers, and military personnel on duty. Despite the consistent 21% oxygen content in the atmosphere, ascending to higher altitudes results in a decrease in the partial pressure of oxygen, inducing a state known as hypobaric hypoxia (HH). HH is an environmental stress that is responsible for neuroinflammation and behavioral deficits (anxiety, depression, mood disturbance, etc.), but little is known about its metabolic pathways. The kynurenine pathway (KP) is a promising candidate to uncover the mysteries of HH stress, as it is an important regulator of the immune system and is associated with behavioral deficits. To investigate the role of KP under HH, the levels of KP metabolites in the serum, cerebrospinal fluid (CSF), and brain tissue (prefrontal cortex-PFC, neocortex, and hippocampus) of male Sprague–Dawley rats exposed to HH at 7620 m for 1, 3, and 7 days were estimated utilizing high-performance liquid chromatography (HPLC). The behavioral analogs for anxiety-like and depression-like behavior were assessed using the open field test and forced swim test, respectively. Upon HH exposure, crosstalk between the periphery and central nervous system and KP metabolite region-dependent differential expression in the brain were observed. KP metabolites showed a positive correlation with behavioral parameters. The results of our study are indicative that KP can be proposed as the etiology of behavioral deficits, and KP metabolite levels in serum or CSF can be used as plausible markers for anxiety-like and depression-like behaviors under HH stress with a scope of targeted therapeutic interventions

Predicting Tachypleus gigas spawning distribution with climate change in northeast coast of India

Species distribution models are used to predict ideal grounds, species range, and spatial shifts in an ecology over a span of time. With an aim to use Maximum entropy model (MaxEnt), presence records and pseudo-absence points are used to predict the Tachypleus gigas spawning activity for 2030 and 2050 in northeast India. The bearings of sixty T. gigas spawning grounds identified in 2018 were inserted into ArcGIS v.10.1. Meanwhile, 19 environment variables were inserted into MaxEnt v. 3.3.3, before the model performance was tested using receiver operational characteristics and area under curve (AUC). With an AUC of 0.978,85% was achieved for isothermality (bio3) and 74% for temperature (x̄= average) of the wettest quarter (bio8), all of which were inserted into ArcGIS to produce spatial maps. Although we learnt that T. gigas are still spawning in Odisha in 2030 and 2050, their distribution range is predicted to shrink due to the coastal morphology change. The climate conditions in Odisha revolve with the monsoon, summer and winter seasons from which, temperature variations do not only influence the annual absence/presence of spawning adults but also, the survival of juveniles in natal beaches. The use of MaxEnt offers novelty to predict population sustainability of arthropods characterized by oviparous spawning (horseshoe crabs, turtles, terrapins and crocodiles) through which, the government of India can take advantage of the present data to initiate the coastal rehabilitation measures to preserve their spawning grounds

Consensus and evidence-based Indian initiative on obstructive sleep apnea guidelines 2014 (first edition)

Obstructive sleep apnea (OSA) and obstructive sleep apnea syndrome (OSAS) are subsets of sleep-disordered breathing. Awareness about OSA and its consequences among the general public as well as the majority of primary care physicians across India is poor. This necessitated the development of the Indian initiative on obstructive sleep apnea (INOSA) guidelines under the auspices of Department of Health Research, Ministry of Health and Family Welfare, Government of India. OSA is the occurrence of an average five or more episodes of obstructive respiratory events per hour of sleep with either sleep-related symptoms or co-morbidities or ≥15 such episodes without any sleep-related symptoms or co-morbidities. OSAS is defined as OSA associated with daytime symptoms, most often excessive sleepiness. Patients undergoing routine health check-up with snoring, daytime sleepiness, obesity, hypertension, motor vehicular accidents, and high-risk cases should undergo a comprehensive sleep evaluation. Medical examiners evaluating drivers, air pilots, railway drivers, and heavy machinery workers should be educated about OSA and should comprehensively evaluate applicants for OSA. Those suspected to have OSA on comprehensive sleep evaluation should be referred for a sleep study. Supervised overnight polysomnography is the "gold standard" for evaluation of OSA. Positive airway pressure (PAP) therapy is the mainstay of treatment of OSA. Oral appliances (OA) are indicated for use in patients with mild to moderate OSA who prefer OA to PAP, or who do not respond to PAP or who fail treatment attempts with PAP or behavioral measures. Surgical treatment is recommended in patients who have failed or are intolerant to PAP therapy

Consensus & Evidence-based INOSA Guidelines 2014 (First edition)

Obstructive sleep apnoea (OSA) and obstructive sleep apnoea syndrome (OSAS) are subsets of sleep-disordered breathing. Awareness about OSA and its consequences amongst the general public as well as the majority of primary care physcians across India is poor. This necessiated the development of the INdian initiative on Obstructive sleep apnoea (INOSA) guidelines under the auspices of Department of Health Research, Ministry of Health & Family Welfare, Government of India. OSA is the occurrence of an average five or more episodes of obstructive respiratory events per hour of sleep with either sleep related symptoms or co-morbidities or ≥ 15 such episodes without any sleep related symptoms or co-morbidities. OSAS is defined as OSA associated with daytime symptoms, most often excessive sleepiness. Patients undergoing routine health check-up with snoring, daytime sleepiness, obesity, hypertension, motor vehicular accidents and high risk cases should undergo a comprehensive sleep evaluation. Medical examiners evaluating drivers, air pilots, railway drivers and heavy machinery workers should be educated about OSA and should comprehensively evaluate applicants for OSA. Those suspected to have OSA on comprehensive sleep evaluation should be referred for a sleep study. Supervised overnight polysomnography (PSG) is the "gold standard" for evaluation of OSA. Positive airway pressure (PAP) therapy is the mainstay of treatment of OSA. Oral appliances are indicated for use in patients with mild to moderate OSA who prefer oral appliances to PAP, or who do not respond to PAP or who fail treatment attempts with PAP or behavioural measures. Surgical treatment is recommended in patients who have failed or are intolerant to PAP therapy